Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of Tanfanercept (HL036) for dry eye disease has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• Tanfanercept (HL036) (tanfanercept)

Snippet

Sponsor: HanAll BioPharma Co., Ltd. | Conditions: Dry Eye | Phase 3 | Status: SUSPENDED